Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 347

The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.

Simvastatin for the Prevention of Exacerbations in Moderate-to-Severe COPD

Open access
Criner, Gerard J., Connett, John E., Aaron, Shawn D., Albert, Richard K., Bailey, William C., Casaburi, Richard, Cooper, J. Allen D., Curtis, Jeffrey L., Dransfield, Mark T., Han, MeiLan K., Make, Barry, Marchetti, Nathaniel, Martinez, Fernando J., Niewoehner, Dennis E., Scanlon, Paul D., Sciurba, Frank C., Scharf, Steven M., Sin, Don D., Voelker, Helen, Washko, George R., Woodruff, Prescott G., Lazarus, Stephen C.·2014·New England Journal of Medicine

Abstract

BACKGROUND: Retrospective studies have shown that statins decrease the rate and severity of exacerbations, the rate of hospitalization, and mortality in chronic obstructive pulmonary disease (COPD). We prospectively studied the efficacy of simvastatin in preventing exacerbations in a large, multicenter, randomized trial. METHODS: We designed the Prospective Randomized Placebo-Controlled Trial of Simvastatin in the Prevention of COPD Exacerbations (STATCOPE) as a randomized, controlled trial of simvastatin (at a daily dose of 40 mg) versus placebo, with annual exacerbation rates as the primary outcome. Patients were eligible if they were 40 to 80 years of age, had COPD (defined by a forced expiratory volume in 1 second [FEV1] of less than 80% and a ratio of FEV1 to forced vital capacity of less than 70%), and had a smoking history of 10 or more pack-years, were receiving supplemental oxygen or treatment with glucocorticoids or antibiotic agents, or had had an emergency department visit or hospitalization for COPD within the past year. Patients with diabetes or cardiovascular disease and those who were taking statins or who required statins on the basis of Adult Treatment Panel III criteria were excluded. Participants were treated from 12 to 36 months at 45 centers. RESULTS: A total of 885 participants with COPD were enrolled for approximately 641 days; 44% of the patients were women. The patients had a mean (±SD) age of 62.2±8.4 years, an FEV1 that was 41.6±17.7% of the predicted value, and a smoking history of 50.6±27.4 pack-years. At the time of study closeout, the low-density lipoprotein cholesterol levels were lower in the simvastatin-treated patients than in those who received placebo. The mean number of exacerbations per person-year was similar in the simvastatin and placebo groups: 1.36±1.61 exacerbations and 1.39±1.73 exacerbations, respectively (P=0.54). The median number of days to the first exacerbation was also similar: 223 days (95% confidence interval [CI], 195 to 275) and 231 days (95% CI, 193 to 303), respectively (P=0.34). The number of nonfatal serious adverse events per person-year was similar, as well: 0.63 events with simvastatin and 0.62 events with placebo. There were 30 deaths in the placebo group and 28 in the simvastatin group (P=0.89). CONCLUSIONS: Simvastatin at a daily dose of 40 mg did not affect exacerbation rates or the time to a first exacerbation in patients with COPD who were at high risk for exacerbations. (Funded by the National Heart, Lung, and Blood Institute and the Canadian Institutes of Health Research; STATCOPE ClinicalTrials.gov number, NCT01061671.).

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejmoa1403086

Cites

45 of 45 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 45 references

Cited by

See all 347

Metadata

Authors
Criner, G. J., Connett, J. E., Aaron, S. D., Albert, R. K., Bailey, W. C., Casaburi, R., Cooper, J. A. D., Curtis, J. L., Dransfield, M. T., Han, M. K., Make, B., Marchetti, N., Martinez, F. J., Niewoehner, D. E., Scanlon, P. D., Sciurba, F. C., Scharf, S. M., Sin, D. D., Voelker, H., Washko, G. R., Woodruff, P. G., & Lazarus, S. C.
Venue
New England Journal of Medicine
Published
2014-06-05
Volume
370
Issue
23
Pages
2201-2210
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W2100858113
Cited by
347
References
45
FWCI
36.83
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Simvastatin for the Prevention of Exacerbations in Moderate-to-Severe COPD. https://app.cochat.ai/papers/10.1056/nejmoa1403086
The paper
Criner, G. J., Connett, J. E., Aaron, S. D., Albert, R. K., Bailey, W. C., Casaburi, R., Cooper, J. A. D., Curtis, J. L., Dransfield, M. T., Han, M. K., Make, B., Marchetti, N., Martinez, F. J., Niewoehner, D. E., Scanlon, P. D., Sciurba, F. C., Scharf, S. M., Sin, D. D., Voelker, H., . . . Lazarus, S. C. (2014). Simvastatin for the Prevention of Exacerbations in Moderate-to-Severe COPD. New England Journal of Medicine. https://doi.org/10.1056/nejmoa1403086

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.